Retour aux appels d'offres

Médicament Polatuzumab vedotin (Appel d'offres ouvert simplifié)

Ouvert
Date limite
2 jours restants
Mars 05, 2026
Détails du contrat
Catégorie
Autre
Référence
6650749
Valeur
Non divulgué
Lieu
Kaunas County, Lituanie
Publié
Février 23, 2026
Code CPV
Calendrier du projet

Publication de l'appel d'offres

Février 23, 2026

Date limite pour les questions

Février 26, 2026

Date limite de soumission

Mars 05, 2026

Ouverture de l'appel d'offres

Mars 05, 2026

Probabilité de gainPRO
🔒
Passer au Professionnel
Consultez votre probabilité de gain estimée basée sur les données historiques.
Passer au Professionnel →
Aperçu du secteurPRO
🔒
Débloquer les aperçus du secteur
Consultez les prix gagnants moyens, les niveaux de concurrence et les tendances du marché.
Passer au Professionnel →
Budget
Non divulgué
Durée
24 mois
Lieu
Kaunas County
Type
Autre
75
Score de qualité/100
Bon
Référentiel de marché
Prix moyen gagnant
€50,148
Offres moyennes
7.2
Concurrence
Élevée
PME gagnantes
99%
54,649 appels d'offres analysés

Description originale de l'appel d'offres

Médicament Polatuzumab vedotin
Achats écologiquesFinancement UE

Analyse des risques

Veuillez vous connecter pour utiliser l'analyse des risques.

Se connecter

Stratégie gagnante

Connectez-vous pour accéder aux recommandations de stratégie gagnante.

Se connecter

Concurrents

Passez à un plan supérieur pour voir quelles entreprises sont susceptibles de soumissionner pour cet appel d'offres, basé sur les données historiques.

Se connecter

Exigences et qualifications

5 exigences dans 5 catégories

Soumission (1)
Obligatoire (1)
Conformité (1)
Technique (1)
Financier (1)
SUBMISSION REQUIREMENTS1
--*
MANDATORY EXCLUSION GROUNDS1
--*
ELIGIBILITY REQUIREMENTS1
--*
TECHNICAL CAPABILITY REQUIREMENTS1
--*
FINANCIAL REQUIREMENTS1
--*

Aperçu des exigences

Inscrivez-vous pour consulter les exigences et l'analyse complètes

Documents

9 documents disponibles avec des résumés IA

Konkurso sąlygosDOC
Konkurso sąlygos.docx

This document contains the tender conditions for the procurement of the medication Polatuzumab vedotin by the Lithuanian University of Health Sciences Hospital Kauno klinikos.

Sutarties specialiosios sąlygos_2 priedasDOC
Sutarties specialiosios sąlygos_2 priedas.doc...

This document contains the special terms and conditions for the purchase and sale of the medication Polatuzumab vedotin.

Europos bendrasis viešųjų pirkimų dokumentas (EBVPD)_3 priedasPDF
Europos bendrasis viešųjų pirkimų dokumentas ...

This document is the European Single Procurement Document (ESPD) Annex 3, used for the procurement of the medication Polatuzumab vedotin by the Lithuanian University of Health Sciences Hospital Kaunas Clinics.

NoticePDF
Notice_6650749.pdf

This document contains a tender notice for the procurement of the medication Polatuzumab vedotin by the Lithuanian University of Health Sciences Hospital Kauno Klinikos.

Sutarties bendrosios sąlygosPDF
Sutarties bendrosios sąlygos.pdf

This document contains the general terms and conditions for the purchase and sale of goods, specifically defining terms and outlining the interpretation and hierarchy of contract documents in the context of procuring the medication Polatuzumab vedotin.

Techninė specifikacijaPDF
Techninė specifikacija.pdf

This document contains the technical specification for the drug Polatuzumab vedotin, outlining requirements for its registration, labeling, and shelf life.

Prekių žiniaraštis_4 priedasXLS
Prekių žiniaraštis_4 priedas.XLS

This document contains a price list for the medication Polatuzumab vedotin, specifying its quantity, unit price, and other relevant details for a tender.

Tender Structure XML - Cycle 1XML
c4t_6650749_1.xml

This document contains the structure for a complete tender submission, requiring a file upload for the 'File' criterion.

Europos bendrasis viešųjų pirkimų dokumentas (EBVPD)_3 priedasXML
Europos bendrasis viešųjų pirkimų dokumentas ...

This document contains a request for information regarding participation in a criminal organization as an exclusion criterion for the tender of Polatuzumab vedotin.

Aperçu des documents

Inscrivez-vous pour consulter les résumés et l'analyse des documents

75
Bon

Score de qualité de l'appel d'offres

This tender for Polatuzumab vedotin is generally well-structured with clear documentation, but lacks specific details on evaluation criteria and financial aspects, impacting its overall completeness and practicality.

Répartition du score

Conformité légale75/100

The tender adheres to EU procurement directives and utilizes standard procedures. The CPV code is appropriate. However, the absence of a revealed date for opening and the lack of specified evaluation criteria are minor procedural shortcomings.

Missing reveal date for opening
No evaluation criteria specified
Clarté80/100

The tender title, description, and classification are clear. Key documents like the ESPD, tender conditions, and technical specifications are provided, offering a good understanding of the procurement's nature. However, the lack of explicit eligibility and technical capability requirements leaves some ambiguity.

No specific eligibility requirements provided
No specific technical capability requirements provided
Exhaustivité70/100

Most basic information is present, including the organization, reference, and contract duration. Several essential documents are attached. However, the estimated value is not disclosed, and specific requirements for exclusion, eligibility, technical, and financial capabilities are missing, reducing overall completeness.

Estimated Value not disclosed
Mandatory exclusion grounds not specified
Équité85/100

The tender is open and utilizes e-procurement, promoting fairness. The CPV code is standard. The value is not disclosed, which is a minor concern for transparency. There are no apparent requirements tailored to specific companies.

Estimated Value not disclosed
Aspect pratique65/100

The tender is EU funded and uses e-procurement, which are positive. However, the lack of explicit information on e-submission process details, contract start date, and financing details beyond 'EU Funded' limits its practicality.

No explicit e-submission details
Contract start date not specified
Cohérence des données90/100

Key fields such as title, reference, organization, and CPV code are populated correctly. The dates provided are logical, and there are no reported disputes or suspensions. The contract duration is clearly stated.

Durabilité50/100

The tender is marked as EU funded, which often implies adherence to certain standards. However, there are no explicit mentions of green procurement, social aspects, or innovation within the provided information.

No explicit green procurement criteria
No explicit social criteria

Points forts

Clear title and reference number
Appropriate CPV code provided
Essential documents attached and analyzed
EU funded and e-procurement utilized

Préoccupations

Estimated value not disclosed
Missing evaluation criteria
Lack of specific requirements (exclusion, eligibility, technical, financial)
Limited sustainability considerations

Recommandations

1. Disclose the estimated value of the procurement.
2. Clearly define the evaluation criteria.
3. Specify all mandatory exclusion, eligibility, technical, and financial requirements.

Aperçu de la notation IA

Inscrivez-vous pour consulter les exigences et l'analyse complètes

Analyse complète du score de qualité
Répartition détaillée des sous-scores
Aperçu des forces et des préoccupations
Recommandations stratégiques

Aucune carte de crédit requise • Configuration en 2 minutes

Ajouter au Pipeline